XML 33 R29.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Segment Information (Tables) | 9 Months Ended
--- | ---
Mar. 31, 2014
Segment Reporting [Abstract] |
Revenue by Reportable Segment | The following tables present revenue for each reportable segment and Corporate:
| Three Months Ended March 31
(in millions) | 2014 |  | 2013
Pharmaceutical (1) | $ | 18,762 |  |  | $ | 22,070 |
Medical | 2,657 |  |  | 2,484 |
Total segment revenue | 21,419 |  |  | 24,554 |
Corporate (2) | 8 |  |  | (2 | )
Total revenue | $ | 21,427 |  |  | $ | 24,552 |
| Nine Months Ended March 31
(in millions) | 2014 |  | 2013
Pharmaceutical (1) | $ | 60,018 |  |  | $ | 68,314 |
Medical | 8,168 |  |  | 7,363 |
Total segment revenue | 68,186 |  |  | 75,677 |
Corporate (2) | 4 |  |  | (4 | )
Total revenue | $ | 68,190 |  |  | $ | 75,673 |
(1) | The decrease in Pharmaceutical segment revenue is primarily due to the Walgreens contract expiration.
(2) | Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit by Reportable Segment | The following tables present segment profit by reportable segment and Corporate:
| Three Months Ended March 31
(in millions) | 2014 |  | 2013
Pharmaceutical | $ | 452 |  |  | $ | 498 |
Medical | 111 |  |  | 100 |
Total segment profit | 563 |  |  | 598 |
Corporate | (55 | ) |  | (123 | )
Total operating earnings | $ | 508 |  |  | $ | 475 |
| Nine Months Ended March 31
(in millions) | 2014 |  | 2013
Pharmaceutical | $ | 1,368 |  |  | $ | 1,339 |
Medical | 348 |  |  | 268 |
Total segment profit | 1,716 |  |  | 1,607 |
Corporate | (218 | ) |  | (168 | )
Total operating earnings | $ | 1,498 |  |  | $ | 1,439 |
Assets by Reportable Segments | The following table presents total assets for each reportable segment and Corporate:
(in millions) | March 31, 2014 |  | June 30, 2013
Pharmaceutical (1) | $ | 14,447 |  |  | $ | 16,258 |
Medical | 6,376 |  |  | 6,521 |
Corporate | 3,878 |  |  | 3,040 |
Total assets | $ | 24,701 |  |  | $ | 25,819 |
(1) | The decrease in Pharmaceutical segment assets is primarily due to the Walgreens contract expiration.

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total profit or loss from reportable segments, to the entity's consolidated income before income taxes, extraordinary items, and discontinued operations. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration